Murilo Freitas – Página 119

ICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%, An Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter

Murilo Freitas - 04:00, 6 de septiembre de 2021566

ICU Medical, Inc. is voluntarily recalling one lot (2,112 units) of Aminosyn II, 15%, An Amino Acid Injection, Sulfite Free intravenous (IV) solution to the hospital/user level due to the presence of visible particulate matter identified as fibers, hair, and proteinaceous material along with other

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-issues-voluntary-nationwide-recall-aminosyn-ii-15-amino-acid-injection-sulfite-free-iv

rss rss-es rss-pt

Primera semana de septiembre se convierte en la segunda con mayor cantidad de casos COVID-19

Murilo Freitas - 19:25, 5 de septiembre de 20211,047

Primera semana de septiembre se convierte en la segunda con mayor cantidad de casos COVID-19

Lunes 6 de setiembre, 2021. La semana epidemiológica 35 que abarcó del 29 de agosto al 4 de setiembre registró 16.601 casos de COVID-19...

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2167-primera-semana-de-septiembre-se-convierte-en-la-segunda-con-mayor-cantidad-de-casos-covid-19

rss rss-es rss-pt

Teligent Pharma, Inc.’s Issues Voluntary Recall of Lidocaine HCl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due to Super Potency

Murilo Freitas - 16:15, 2 de septiembre de 2021560

Teligent Pharma, Inc. is voluntarily recalling one lot of Lidocaine HCl Topical Solution 4%, 50ml in a screw cap glass bottle to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-m

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teligent-pharma-incs-issues-voluntary-recall-lidocaine-hcl-topical-solution-4-lot-14218-exp-092022

rss rss-es rss-pt

FDA In Brief: FDA Reaches Milestone in Competitive Generic Therapy Drug Approvals

Murilo Freitas - 15:14, 1 de septiembre de 2021469

FDA In Brief: FDA Reaches Milestone in Competitive Generic Therapy Drug Approvals
http://www.fda.gov/news-events/press-announcements/fda-brief-fda-reaches-milestone-competitive-generic-therapy-drug-approvals

rss rss-es rss-pt

Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare® Test Kits

Murilo Freitas - 04:00, 1 de septiembre de 2021620

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. (“Magellan”), expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead T

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/magellan-diagnostics-inc-expands-voluntary-recall-leadcarer-test-kits

rss rss-es rss-pt

Quercetin with Vitamin C/Quercetin 15x (2021-09-02)

Murilo Freitas - 04:00, 1 de septiembre de 2021490

Quercetin with Vitamin C/Quercetin 15x (2021-09-02)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76377r-eng.php

rss rss-es rss-pt

Eco-Med Prevent Hand Sanitizer (2021-09-02)

Murilo Freitas - 04:00, 1 de septiembre de 2021499

Eco-Med Prevent Hand Sanitizer (2021-09-02)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76383r-eng.php

rss rss-es rss-pt

FDA In Brief: FDA to Hold Advisory Committee Meeting to Discuss Pfizer-BioNTech’s Application for COVID-19 Booster

Murilo Freitas - 20:54, 31 de agosto de 2021455

FDA In Brief: FDA to Hold Advisory Committee Meeting to Discuss Pfizer-BioNTech’s Application for COVID-19 Booster
http://www.fda.gov/news-events/press-announcements/fda-brief-fda-hold-advisory-committee-meeting-discuss-pfizer-biontechs-application-covid-19-booster

rss rss-es rss-pt

Entidades nos invitan a escuchar y actuar en comunidad para prevenir el comportamiento suicida

Murilo Freitas - 16:02, 31 de agosto de 2021512

Entidades nos invitan a escuchar y actuar en comunidad para prevenir el comportamiento suicida

01 de setiembre del 2021. San José. Con el objetivo de sensibilizar a la población, abordar los estigmas y mitos que acompañan al comportamiento suicida...

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2166-entidades-nos-invitan-a-escuchar-y-actuar-en-comunidad-para-prevenir-el-comportamiento-suicida

rss rss-es rss-pt

Janus Kinase (JAK) inhibitors: Drug Safety Communication – FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death

Murilo Freitas - 04:00, 31 de agosto de 2021574

FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.

http://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk